Search the Newsreel

Is Arrowhead Pharmaceuticals Stock A Smart Buy After Its Transition To A Commercial Company?

Arrowhead Pharmaceuticals (ARWR) has transitioned into a commercial company with its first approved drug, REDEMPLO, and a strong pipeline. While the stock has seen significant growth and has a high valuation, indicating market belief in future potential, its history shows high volatility and deep …

Morgan Stanley Forecasts Strong Price Appreciation for Arrowhead Pharmaceuticals (NASDAQ:ARWR) Stock

Arrowhead Pharmaceuticals (ARWR) Hits 52-Week High Following Pos

Arrowhead Pharmaceuticals (ARWR) reached a new 52-week high after reporting successful late-stage trial results for its lipid-lowering drug, plozasiran, which showed an 81% median triglyceride reduction. Despite the positive news and a significant market cap of $13.02 billion, the company holds a low GF …

Arrowhead Pharmaceuticals Inc Stock (ARWR) Closed Up by 19.04% on Jul 22: What Signal Does It Send?

Arrowhead Pharmaceuticals Inc. (ARWR) stock rose 19.04% on July 22, driven by positive Phase 3 clinical trial results for its RNA interference candidate in cardiometabolic disorders. Despite the strong fundamental news and analyst price target increases, technical indicators like MACD and Williams %R suggest …

Arrowhead (ARWR) Soars to New High as Plozasiran Nears Expanded Commercialization

Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) skyrocketed to a five-year high on Wednesday, as investors began positioning portfolios ahead of the supplemental new drug application (sNDA) of its drug candidate, plozasiran, for the treatment of severe hypertriglyceridemia. In intra-day trading, the stock soared by as much …

Arrowhead Drug Shows Strong Efficacy In Cutting Blood Fat

Arrowhead Pharmaceuticals' (NASDAQ: ARWR) drug plozasiran has shown strong efficacy in reducing triglyceride levels and acute pancreatitis occurrences in patients with severe hypertriglyceridemia across two Phase 3 trials, SHASTA-3 and SHASTA-4. Patients receiving 25 mg quarterly saw significant reductions in triglyceride levels, and high-risk …

Top Midday Gainers

Arrowhead Pharmaceuticals (ARWR) said Wednesday topline results from its global phase 3 clinical stu PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premium news articles. Upgrade Already have a …

Arrowhead Pharmaceuticals (ARWR) Stock Looks Fairly Priced With Strong Sales But A Demanding 398% Run

Arrowhead Pharmaceuticals has seen an extreme 398.1% gain over the past year, leading to a valuation that is now considered fairly priced rather than an obvious bargain. While the recent European Commission authorization for Redemplo supports higher revenue expectations, clinical and reimbursement uncertainties for …

Arrowhead Pharmaceuticals Reports Topline Results from Phase 3 SHASTA-3 and SHASTA-4 Studies of Plozasiran in Patients with Severe Hypertriglyceridemia

Arrowhead Pharmaceuticals announced positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 clinical studies of plozasiran for severe hypertriglyceridemia (sHTG). The drug achieved deep and consistent triglyceride reductions of 79% and 81%, respectively, and statistically significant reductions in acute pancreatitis events, including a …

Why Arrowhead Pharmaceuticals Is Surging 24.4%: JP Morgan Maintains Overweight

Arrowhead Pharmaceuticals (ARWR) surged 24.4% to $92.72 after JP Morgan upgraded the biotech's rating to Overweight and raised its price target from $88 to $95. This upgrade was attributed to positive regulatory signals from the FDA, energizing investor interest in the RNAi therapeutics developer. …

ARWR Jumps As REDEMPLO Win Fuels Bullish Targets

Arrowhead Pharmaceuticals Inc. (ARWR) stock jumped over 22% after European regulators approved its drug REDEMPLO for familial chylomicronemia syndrome, backed by strong Phase 3 data. This approval, combined with bullish analyst targets from Stifel and JPMorgan anticipating a $3B market for upcoming severe hypertriglyceridemia …

Ionis drops as Arrowhead posts late-stage trial win for lipid-lowering drug

Arrowhead Pharmaceuticals announced positive late-stage trial results for its lipid-lowering drug, plozasiran, intended for patients with severe hypertriglyceridemia. This news negatively impacted Ionis Pharmaceuticals, a competitor in the same therapeutic area. An earlier version of the story was corrected to reflect that Ionis Pharma's …

Arrowhead Pharmaceuticals shares surge after positive Phase 3 results for plozasiran (NASDAQ:ARWR)

Arrowhead Pharmaceuticals (NASDAQ:ARWR) saw its shares jump 18% after announcing positive topline data from its Phase 3 SHASTA-3 and SHASTA-4 clinical trials for plozasiran. The trials successfully met all primary and secondary endpoints, showing significant reductions in triglyceride levels and a favorable safety profile …

ARWR: SHASTA-3 and SHASTA-4 Hit on All Endpoints Including 100% Reduction in Acute Pancreatitis in High-Risk Patients

By David Bautz, PhD NASDAQ: ARWR READ THE FULL ARWR RESEARCH REPORT Business Update Best Case Scenario for SHASTA-3 and SHASTA-4 Results On July 22, 2026, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) announced positive topline results for the SHASTA-3 and SHASTA-4 trials of plozasiran in patients …

Arrowhead: Stock Up On SHTG Data - No Ceiling On Valuation Growth Potential (NASDAQ:ARWR)

Arrowhead Pharmaceuticals to Webcast Fiscal 2026 Third Quarter Results

Arrowhead Pharmaceuticals announced it will host a webcast and conference call on August 4, 2026, at 4:30 p.m. ET to discuss its financial results for the fiscal 2026 third quarter, which ended June 30, 2026. Investors can access the live audio webcast and its …

ARWR6277444 Bond Risk Profile

This article provides a risk profile for the Arrowhead Pharmaceuticals, Inc. bond ARWR6277444, maturing on January 15, 2032. It highlights key metrics for credit risk assessment, including security level and issuer rating. The profile also mentions the availability of exclusive analyst ratings for bonds.

Is Arrowhead Pharmaceuticals (ARWR) Undervalued Or Is Its Pipeline Promise Already Priced In?

Arrowhead Pharmaceuticals (ARWR) has seen recent stock volatility, with a 4.1% gain in the past day but an 8.3% drop over the last month, yet a strong 1-year return. Analysts view the stock as undervalued with a fair value of $89.08 against its current …

ARWR Maintained by JP Morgan -- Price Target Raised to $95.00

JP Morgan has maintained an "Overweight" rating for Arrowhead Pharmaceuticals Inc. (ARWR) and raised its price target from $88.00 to $95.00, signaling increased confidence in the company's future. Despite this, GuruFocus data indicates ARWR is currently overvalued by 46.4% based on its GF Value, …

J.P. Morgan Maintains Arrowhead Pharmaceuticals(ARWR.US) With Buy Rating, Raises Target Price to $95

J.P. Morgan has reiterated its Buy rating on Arrowhead Pharmaceuticals (ARWR.US) and increased its price target for the company to $95. This revised target suggests potential upside for investors in Arrowhead Pharmaceuticals.

6 Red Days In A Row: Arrowhead Pharmaceuticals Stock Is Down 17%

Arrowhead Pharmaceuticals (ARWR) stock has dropped 17.4% over six consecutive trading days, resulting in a $2.2 billion market value decrease. This decline is company-specific, as the S&P 500 gained 0.9% during the same period, and is attributed to strained profitability metrics despite high historical …

Has Arrowhead Pharmaceuticals (ARWR) Run Too Far After Its 488% One Year Surge

Arrowhead (ARWR) Q2 2026 Earnings Transcript

Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results

The Bull Case For Arrowhead Pharmaceuticals (ARWR) Could Change Following Australian Approval Of REDEMPLO For FCS

Arrowhead Pharmaceuticals' (NASDAQ:ARWR) Strong Earnings Are Of Good Quality

Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Stock Catapults 33% Though Its Price And Business Still Lag The Industry

Arrowhead Pharmaceuticals Inc (ARWR) Q4 2025 Earnings Call Highlights: FDA Approval and ...